889 related articles for article (PubMed ID: 36988873)
1. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
[TBL] [Abstract][Full Text] [Related]
2. Delivery of Tissue-Targeted Scalpels: Opportunities and Challenges for
Wei T; Cheng Q; Farbiak L; Anderson DG; Langer R; Siegwart DJ
ACS Nano; 2020 Aug; 14(8):9243-9262. PubMed ID: 32697075
[TBL] [Abstract][Full Text] [Related]
3. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
4. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical non-viral vectors exploited for
Rouatbi N; McGlynn T; Al-Jamal KT
Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
[TBL] [Abstract][Full Text] [Related]
6. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities.
Li L; Hu S; Chen X
Biomaterials; 2018 Jul; 171():207-218. PubMed ID: 29704747
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanoparticles: The game-changer in CRISPR-Cas9 genome editing.
Mohammadian Farsani A; Mokhtari N; Nooraei S; Bahrulolum H; Akbari A; Farsani ZM; Khatami S; Ebadi MS; Ahmadian G
Heliyon; 2024 Jan; 10(2):e24606. PubMed ID: 38288017
[TBL] [Abstract][Full Text] [Related]
8. Recent Advances in CRISPR/Cas9 Delivery Strategies.
Yip BH
Biomolecules; 2020 May; 10(6):. PubMed ID: 32486234
[TBL] [Abstract][Full Text] [Related]
9. Delivery Approaches for Therapeutic Genome Editing and Challenges.
Ates I; Rathbone T; Stuart C; Bridges PH; Cottle RN
Genes (Basel); 2020 Sep; 11(10):. PubMed ID: 32977396
[TBL] [Abstract][Full Text] [Related]
10. Delivery approaches for CRISPR/Cas9 therapeutics in vivo: advances and challenges.
Luther DC; Lee YW; Nagaraj H; Scaletti F; Rotello VM
Expert Opin Drug Deliv; 2018 Sep; 15(9):905-913. PubMed ID: 30169977
[TBL] [Abstract][Full Text] [Related]
11. Delivery of CRISPR/Cas9 for therapeutic genome editing.
Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Genome Editing and In Vivo Delivery.
Ramirez-Phillips AC; Liu D
AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
[TBL] [Abstract][Full Text] [Related]
14. Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management.
Allemailem KS; Alsahli MA; Almatroudi A; Alrumaihi F; Alkhaleefah FK; Rahmani AH; Khan AA
Cancer Commun (Lond); 2022 Dec; 42(12):1257-1287. PubMed ID: 36209487
[TBL] [Abstract][Full Text] [Related]
15. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
Chen F; Alphonse M; Liu Q
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
[TBL] [Abstract][Full Text] [Related]
16. Different Methods of Delivering CRISPR/Cas9 Into Cells.
Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
[TBL] [Abstract][Full Text] [Related]
17. Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading.
Liang Y; Iqbal Z; Wang J; Xu L; Xu X; Ouyang K; Zhang H; Lu J; Duan L; Xia J
Biomater Sci; 2022 Jul; 10(15):4095-4106. PubMed ID: 35766814
[TBL] [Abstract][Full Text] [Related]
18. Challenges in CRISPR/CAS9 Delivery: Potential Roles of Nonviral Vectors.
Li L; He ZY; Wei XW; Gao GP; Wei YQ
Hum Gene Ther; 2015 Jul; 26(7):452-62. PubMed ID: 26176432
[TBL] [Abstract][Full Text] [Related]
19. Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders.
Wan T; Ping Y
Adv Drug Deliv Rev; 2021 Jan; 168():196-216. PubMed ID: 32416111
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9 therapeutics: progress and prospects.
Li T; Yang Y; Qi H; Cui W; Zhang L; Fu X; He X; Liu M; Li PF; Yu T
Signal Transduct Target Ther; 2023 Jan; 8(1):36. PubMed ID: 36646687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
